Indications for: DEPO-TESTOSTERONE
Testosterone replacement therapy.
Limitations of Use:
Not established in men with age-related hypogonadism.
Prior to treatment, confirm diagnosis by ensuring serum testosterone is below normal range as measured in the AM on at least 2 separate days. Give by deep IM inj into gluteal muscle once every 2 to 4 weeks. 50–400mg; max 400mg/month.
Serious cardiac, hepatic, or renal disease. Male breast or prostate cancer. Use in women. Pregnancy (Cat.X).
Discontinue if jaundice, abnormal liver function, hypercalcemia, or edema occurs. Monitor liver function, hemoglobin, hematocrit, prostate specific antigen (PSA), cholesterol, bone age. Cardiac, hepatic, or renal dysfunction. May increase risk of prostatic hyperplasia in elderly. May increase growth of subclinical prostatic carcinoma. Monitor for venous thromboembolism; discontinue if suspected. Inform patients of possible increased risk of MI, stroke. Elderly. Young children. Nursing mothers: not recommended.
May potentiate oral anticoagulants, oxyphenbutazone. May alter insulin effects. Increased risk of edema with ACTH, corticosteroids.
Inj site reactions, peliosis hepatis, premature epiphyseal closure in adolescents, edema, hepatic carcinoma, prostatic hypertrophy or carcinoma, gynecomastia, priapism, oligospermia, nausea, jaundice, hirsutism, virilization, male pattern baldness, acne, polycythemia, headache, anxiety, depression, paresthesias, altered libido, fluid and electrolyte disturbances, suppression of clotting factors, increased serum cholesterol.
Vial 100mg/mL (10mL)–1; Vial 200mg/mL (1mL, 10mL)–1